Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Tus-Guhan GroupLtd

SZSE:000590
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
000590
SZSE
CN¥2B
Market Cap
  1. Home
  2. CN
  3. Pharmaceuticals & Biotech
Company description

Tus-Guhan Group Corp.,Ltd. researches, develops, manufactures, and sells traditional Chinese medicine recipes, and prescriptions and western medicine preparations. The last earnings update was 161 days ago. More info.


Add to Portfolio Compare Print
000590 Share Price and Events
7 Day Returns
-5.7%
SZSE:000590
0.3%
CN Pharmaceuticals
-0.1%
CN Market
1 Year Returns
-42.3%
SZSE:000590
2.1%
CN Pharmaceuticals
-9.3%
CN Market
000590 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Tus-Guhan GroupLtd (000590) -5.7% -9.5% -16.7% -42.3% -49% -61.7%
CN Pharmaceuticals 0.3% -3.8% 5.7% 2.1% 0.1% -4.7%
CN Market -0.1% -10.6% -6.3% -9.3% -16.2% -26.5%
1 Year Return vs Industry and Market
  • 000590 underperformed the Pharmaceuticals industry which returned 2.1% over the past year.
  • 000590 underperformed the Market in China which returned -9.3% over the past year.
Price Volatility
000590
Industry
5yr Volatility vs Market

000590 Value

 Is Tus-Guhan GroupLtd undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Tus-Guhan GroupLtd to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Tus-Guhan GroupLtd.

SZSE:000590 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year CN Government Bond Rate 3.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SZSE:000590
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CN Govt Bond Rate 3.2%
Equity Risk Premium S&P Global 6.3%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.686 (1 + (1- 25%) (1.24%))
0.794
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.2% + (0.8 * 6.33%)
8.26%

Discounted Cash Flow Calculation for SZSE:000590 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Tus-Guhan GroupLtd is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SZSE:000590 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 8.26%)
2020 9.32 Est @ 84.32% 8.61
2021 14.91 Est @ 59.98% 12.72
2022 21.31 Est @ 42.95% 16.80
2023 27.93 Est @ 31.02% 20.33
2024 34.26 Est @ 22.68% 23.03
2025 40.03 Est @ 16.83% 24.86
2026 45.13 Est @ 12.74% 25.89
2027 49.59 Est @ 9.88% 26.27
2028 53.49 Est @ 7.88% 26.18
2029 56.95 Est @ 6.47% 25.74
Present value of next 10 years cash flows CN¥210.00
SZSE:000590 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥56.95 × (1 + 3.2%) ÷ (8.26% – 3.2%)
CN¥1,160.69
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥1,160.69 ÷ (1 + 8.26%)10
CN¥524.66
SZSE:000590 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥210.00 + CN¥524.66
CN¥734.66
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥734.66 / 239.47
CN¥3.07
SZSE:000590 Discount to Share Price
Calculation Result
Value per share (CNY) From above. CN¥3.07
Current discount Discount to share price of CN¥10.07
= -1 x (CN¥10.07 - CN¥3.07) / CN¥3.07
-228.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Tus-Guhan GroupLtd is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Tus-Guhan GroupLtd's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Tus-Guhan GroupLtd's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SZSE:000590 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CNY CN¥-0.04
SZSE:000590 Share Price ** SZSE (2020-04-03) in CNY CN¥10.07
China Pharmaceuticals Industry PE Ratio Median Figure of 157 Publicly-Listed Pharmaceuticals Companies 30.57x
China Market PE Ratio Median Figure of 3,197 Publicly-Listed Companies 32.34x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Tus-Guhan GroupLtd.

SZSE:000590 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SZSE:000590 Share Price ÷ EPS (both in CNY)

= 10.07 ÷ -0.04

-250.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tus-Guhan GroupLtd is loss making, we can't compare its value to the CN Pharmaceuticals industry average.
  • Tus-Guhan GroupLtd is loss making, we can't compare the value of its earnings to the China market.
Price based on expected Growth
Does Tus-Guhan GroupLtd's expected growth come at a high price?
Raw Data
SZSE:000590 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -250.17x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
China Pharmaceuticals Industry PEG Ratio Median Figure of 55 Publicly-Listed Pharmaceuticals Companies 1.59x
China Market PEG Ratio Median Figure of 1,273 Publicly-Listed Companies 1.27x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Tus-Guhan GroupLtd, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Tus-Guhan GroupLtd's assets?
Raw Data
SZSE:000590 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CNY CN¥2.49
SZSE:000590 Share Price * SZSE (2020-04-03) in CNY CN¥10.07
China Pharmaceuticals Industry PB Ratio Median Figure of 174 Publicly-Listed Pharmaceuticals Companies 2.62x
China Market PB Ratio Median Figure of 3,691 Publicly-Listed Companies 2.26x
SZSE:000590 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SZSE:000590 Share Price ÷ Book Value per Share (both in CNY)

= 10.07 ÷ 2.49

4.04x

* Primary Listing of Tus-Guhan GroupLtd.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tus-Guhan GroupLtd is overvalued based on assets compared to the CN Pharmaceuticals industry average.
X
Value checks
We assess Tus-Guhan GroupLtd's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Tus-Guhan GroupLtd has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

000590 Future Performance

 How is Tus-Guhan GroupLtd expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tus-Guhan GroupLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Tus-Guhan GroupLtd expected to grow at an attractive rate?
  • Unable to compare Tus-Guhan GroupLtd's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Tus-Guhan GroupLtd's earnings growth to the China market average as no estimate data is available.
  • Unable to compare Tus-Guhan GroupLtd's revenue growth to the China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
SZSE:000590 Future Growth Rates Data Sources
Data Point Source Value (per year)
China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 23%
China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 18.2%
China Market Earnings Growth Rate Market Cap Weighted Average 20.9%
China Market Revenue Growth Rate Market Cap Weighted Average 15.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SZSE:000590 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SZSE:000590 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-09-30 271 32 -10
2019-06-30 241 -1 -26
2019-03-31 215 32 -33
2018-12-31 186 1 -38
2018-09-30 203 -14 24
2018-06-30 234 -9 40
2018-03-31 281 -54 45
2017-12-31 293 -87 50
2017-09-30 295 -98 74
2017-06-30 298 -99 74
2017-03-31 279 -103 69
2016-12-31 301 -33 72

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Tus-Guhan GroupLtd is high growth as no earnings estimate data is available.
  • Unable to determine if Tus-Guhan GroupLtd is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SZSE:000590 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Tus-Guhan GroupLtd Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SZSE:000590 Past Financials Data
Date (Data in CNY Millions) EPS *
2019-09-30 -0.04
2019-06-30 -0.11
2019-03-31 -0.14
2018-12-31 -0.16
2018-09-30 0.10
2018-06-30 0.17
2018-03-31 0.19
2017-12-31 0.22
2017-09-30 0.33
2017-06-30 0.33
2017-03-31 0.31
2016-12-31 0.32

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Tus-Guhan GroupLtd will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Tus-Guhan GroupLtd's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Tus-Guhan GroupLtd's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Tus-Guhan GroupLtd's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Tus-Guhan GroupLtd has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

000590 Past Performance

  How has Tus-Guhan GroupLtd performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Tus-Guhan GroupLtd's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Tus-Guhan GroupLtd does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Tus-Guhan GroupLtd's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Tus-Guhan GroupLtd's 1-year growth to the CN Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Tus-Guhan GroupLtd's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Tus-Guhan GroupLtd Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SZSE:000590 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 271.23 -9.64 127.75 9.56
2019-06-30 240.90 -26.26 128.74 9.21
2019-03-31 214.51 -32.85 121.24 8.94
2018-12-31 185.81 -38.18 115.09 7.48
2018-09-30 202.71 24.25 132.86 6.37
2018-06-30 233.69 39.55 139.84 6.49
2018-03-31 280.64 44.82 157.34 6.88
2017-12-31 292.87 50.07 163.94 5.53
2017-09-30 294.64 74.33 143.19 4.23
2017-06-30 297.54 74.09 138.59 2.62
2017-03-31 279.44 69.28 133.07
2016-12-31 301.46 72.07 136.89
2016-09-30 294.72 3.21 128.16
2016-06-30 298.33 23.02 114.00
2016-03-31 300.07 25.60 120.32
2015-12-31 294.72 22.37 120.54
2015-09-30 284.68 -55.63 176.98
2015-06-30 269.40 -76.45 185.98
2015-03-31 235.36 -78.49 169.14
2014-12-31 203.12 -85.77 160.31
2014-09-30 173.79 -164.13 162.66
2014-06-30 175.07 -179.53 171.16
2014-03-31 215.37 -177.22 190.66
2013-12-31 256.00 -164.45 195.05
2013-09-30 323.42 83.35 147.95
2013-06-30 340.42 104.60 168.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Tus-Guhan GroupLtd has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Tus-Guhan GroupLtd has efficiently used its assets last year compared to the CN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Tus-Guhan GroupLtd improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Tus-Guhan GroupLtd's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Tus-Guhan GroupLtd has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

000590 Health

 How is Tus-Guhan GroupLtd's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Tus-Guhan GroupLtd's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Tus-Guhan GroupLtd is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Tus-Guhan GroupLtd's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Tus-Guhan GroupLtd's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 16.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Tus-Guhan GroupLtd Company Filings, last reported 6 months ago.

SZSE:000590 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 597.05 30.00 302.23
2019-06-30 595.09 30.00 299.72
2019-03-31 590.51 30.00 305.67
2018-12-31 579.72 38.00 321.35
2018-09-30 572.12 40.00 221.98
2018-06-30 586.79 20.00 321.51
2018-03-31 588.79 20.00 83.62
2017-12-31 583.33 20.00 317.51
2017-09-30 555.98 24.00 103.79
2017-06-30 556.63 33.50 322.49
2017-03-31 275.30 36.90 43.58
2016-12-31 263.96 78.30 122.67
2016-09-30 224.42 74.55 58.86
2016-06-30 225.22 72.40 77.03
2016-03-31 219.28 50.15 43.59
2015-12-31 205.79 63.95 55.84
2015-09-30 215.44 92.65 58.40
2015-06-30 196.51 94.25 61.83
2015-03-31 195.06 25.00 50.38
2014-12-31 184.11 77.52 67.92
2014-09-30 271.28 50.00 63.39
2014-06-30 271.70 0.50 46.45
2014-03-31 272.59 0.50 64.35
2013-12-31 269.51 0.00 65.72
2013-09-30 435.06 18.17 129.04
2013-06-30 466.64 0.00 142.43
  • Tus-Guhan GroupLtd's level of debt (5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (18.6% vs 5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Information is not available.
  • Unable to confirm if Tus-Guhan GroupLtd has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Tus-Guhan GroupLtd's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Tus-Guhan GroupLtd has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

000590 Dividends

 What is Tus-Guhan GroupLtd's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Tus-Guhan GroupLtd dividends.
If you bought CN¥2,000 of Tus-Guhan GroupLtd shares you are expected to receive CN¥0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Tus-Guhan GroupLtd's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Tus-Guhan GroupLtd's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SZSE:000590 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 137 Stocks 1.2%
China Market Average Dividend Yield Market Cap Weighted Average of 2588 Stocks 1.9%
China Minimum Threshold Dividend Yield 10th Percentile 0.2%
China Bottom 25% Dividend Yield 25th Percentile 0.5%
China Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SZSE:000590 Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2015-04-14 0.000 0.000
2014-10-27 0.000 0.000
2014-07-25 0.000 0.000
2014-04-16 0.000 0.000
2014-03-10 0.000 0.000
2013-06-17 0.400 3.465
2012-10-29 0.182 1.842
2012-10-15 0.182 1.593
2012-08-28 0.182 1.566

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Tus-Guhan GroupLtd has not reported any payouts.
  • Unable to verify if Tus-Guhan GroupLtd's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Tus-Guhan GroupLtd's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Tus-Guhan GroupLtd has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Tus-Guhan GroupLtd's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Tus-Guhan GroupLtd afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Tus-Guhan GroupLtd has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

000590 Management

 What is the CEO of Tus-Guhan GroupLtd's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Tus-Guhan GroupLtd has no CEO, or we have no data on them.
Management Team

Bingcheng Liu

TITLE
Vice President and Non-Independent Director
COMPENSATION
CN¥250K

Dingxing Cao

TITLE
Secretary of the Board
COMPENSATION
CN¥250K
Board of Directors Tenure

Average tenure of the Tus-Guhan GroupLtd board of directors in years:

2.8
Average Tenure
  • The average tenure for the Tus-Guhan GroupLtd board of directors is less than 3 years, this suggests a new board.
Board of Directors

Yi Li

TITLE
Chairman
COMPENSATION
CN¥140K

Bingcheng Liu

TITLE
Vice President and Non-Independent Director
COMPENSATION
CN¥250K
TENURE
2.8 yrs

Linbi Peng

TITLE
Director

Lin Jinting

TITLE
Director
COMPENSATION
CN¥90K
AGE
51

Kang Zhao

TITLE
Director
COMPENSATION
CN¥90K

Fenghua Chen

TITLE
Non-Independent Director
TENURE
2.8 yrs

Shugui Wang

TITLE
Non-Independent Director
AGE
44
TENURE
2.8 yrs

Ming Dan

TITLE
Non-Independent Director
TENURE
2.8 yrs

Shouhui An

TITLE
Independent Director
TENURE
2.8 yrs

Junfeng Liu

TITLE
Independent Director
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CN¥) Value (CN¥)
X
Management checks
We assess Tus-Guhan GroupLtd's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Tus-Guhan GroupLtd has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

000590 News

Simply Wall St News

000590 Company Info

Description

Tus-Guhan Group Corp.,Ltd. researches, develops, manufactures, and sells traditional Chinese medicine recipes, and prescriptions and western medicine preparations. It also provides medicinal wine and health, and investment products. The company was formerly known as Unisplendour Guhan Group Corporation Limited and changed its name to Tus-Guhan Group Corp.,Ltd. in April 2016. Tus-Guhan Group Corp.,Ltd. was founded in 1956 and is based in Hengyang, China.

Details
Name: Tus-Guhan Group Corp.,Ltd.
000590
Exchange: SZSE
Founded: 1956
CN¥2,411,475,658
239,471,267
Website: http://www.guhan.com
Address: Tus-Guhan Group Corp.,Ltd.
No. 33, Yangliu Road,
High-tech Zone,
Hengyang,
Hunan Province, 421001,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SZSE 000590 Domestic Shares Shenzhen Stock Exchange CN CNY 23. Sep 1996
Number of employees
Current staff
Staff numbers
0
Tus-Guhan GroupLtd employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 15:29
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2019/10/28
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.